TD Cowen Initiates Coverage On TG Therapeutics with Buy Rating, Announces Price Target of $50
Portfolio Pulse from Benzinga Newsdesk
TD Cowen has initiated coverage on TG Therapeutics with a Buy rating and set a price target of $50.
October 29, 2024 | 9:53 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
TD Cowen has initiated coverage on TG Therapeutics with a Buy rating and a price target of $50, indicating a positive outlook for the stock.
The initiation of coverage with a Buy rating and a $50 price target by TD Cowen suggests a positive sentiment towards TG Therapeutics. This could lead to increased investor interest and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100